|
Negotiated Medicare Price Discounts to Begin in 2026
|
|
With new negotiations from Washington, D.C., pharmacists should expect lower prices—and copays—for many common medications dispensed to Part D Medicare beneficiaries by 2026. The drugs, which have high list prices, are used to treat heart disease, diabetes, and cancer and are used in about 9 million patients. Find out which medication prices were negotiated.
|
|
|
Tirzepatide Linked to Lower Risks of Death, CVD, Kidney Events
|
|
|
Glucagon-like peptide 1 receptor agonists might have been among the trendiest drugs the last few years, but a new study suggests tirzepatide—a combination marketed as Mounjaro for type 2 diabetes—is linked to lower risks for death, cardiovascular disease (CVD), and adverse kidney effects, according to a report published in the Journal of the American Medical Association. Read more.
|
|
Bone Fracture Risk Extends Beyond Non-Hispanic White Women
|
|
|
Non-Hispanic white women are much more likely to be prescribed medications for osteoporosis because they remain at highest risk for fractures; however, that does not mean other ethnic and racial groups are without risks. Find out what new studies found about fractures among Hispanic and Asian women who live in the United States and are among the fastest-growing ethnic groups in the country.
|
|
|
Starting and Scanning the FreeStyle Libre 3 Sensor
|
|
The FreeStyle Libre 3 system has been cleared by the FDA and is indicated for use in people with diabetes aged 4 years and older. Learn more about the FreeStyle Libre 3 system and how it can be an effective tool for glucose monitoring in diabetes management.
|
|
